This article is more than 5 years old. Information may no longer be current.

Entyvio available in US for treating ulcerative colitis, Crohn's disease

Takeda Pharmaceuticals announced today that Entyvio is now commercially available to US health care providers for the treatment of moderate to severe ulcerative colitis and Crohn’s disease in adult patients, according to a press release.

The announcement follows last month’s dual approval of Entyvio (vedolizumab) by the FDA for treating ulcerative colitis (UC) and Crohn’s disease (CD) in adult patients with moderate to severely active disease, and for whom response to a tumor necrosis factor blocker, immunomodulator or corticosteroids was inadequate.

“We understand how a great need still exists for additional treatment options for ulcerative colitis and Crohn’s disease patients,” Nicole Mowad-Nassar, vice president, marketing, Takeda Pharmaceuticals, said in the release. “We’re pleased that we were able to make Entyvio available for appropriate patients so quickly after receiving FDA approval.”

Entyvio is an integrin receptor antagonist indicated for inducing and maintaining clinical response and remission, improving mucosal endoscopic appearance and achieving corticosteroid-free remission in UC patients. In CD patients, the treatment is indicated for achieving clinical response and remission and achieving corticosteroid-free remission.

Takeda also announced the launch of EntyvioConnect, a service connecting patients with case managers to gain information and access to the new treatment.